Literature DB >> 22190281

Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia.

Eiichi Hinoi1, Hiroki Ochi, Takeshi Takarada, Eri Nakatani, Takashi Iezaki, Hiroko Nakajima, Hiroyuki Fujita, Yoshifumi Takahata, Shinya Hidano, Takashi Kobayashi, Shu Takeda, Yukio Yoneda.   

Abstract

Osteocytes are thought to play a role as a mechanical sensor through their communication network in bone. Although osteocytes are the most abundant cells in bone, little attention has been paid to their physiological and pathological functions in skeletogenesis. Here, we have attempted to delineate the pivotal functional role of osteocytes in regulation of bone remodeling under pathological conditions. We first found markedly increased osteoclastic differentiation by conditioned media (CM) from osteocytic MLO-Y4 cells previously exposed to hypoxia in vitro. Using microarray and real-time PCR analyses, we identified growth differentiation factor 15 (GDF15) as a key candidate factor secreted from osteocytes under hypoxia. Recombinant GDF15 significantly promoted osteoclastic differentiation in a concentration-dependent manner, with concomitant facilitation of phosphorylation of both p65 and inhibitory-κB in the presence of receptor activator of nuclear factor-κB ligand. To examine the possible functional significance of GDF15 in vivo, mice were subjected to ligation of the right femoral artery as a hypoxic model. A significant increase in GDF15 expression was specifically observed in tibias of the ligated limb but not in tibias of the normally perfused limb. Under these experimental conditions, in cancellous bone of proximal tibias in the ligated limb, a significant reduction was observed in bone volume, whereas a significant increase was seen in the extent of osteoclast surface/bone surface when determined by bone histomorphometric analysis. Finally, the anti-GDF15 antibody prevented bone loss through inhibiting osteoclastic activation in tibias from mice with femoral artery ligation in vivo, in addition to suppressing osteoclastic activity enhanced by CM from osteocytes exposed to hypoxia in vitro. These findings suggest that GDF15 could play a pivotal role in the pathogenesis of bone loss relevant to hypoxia through promotion of osteoclastogenesis after secretion from adjacent osteocytes during disuse and/or ischemia in bone.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22190281     DOI: 10.1002/jbmr.1538

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

1.  Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Authors:  Marita Westhrin; Siv Helen Moen; Toril Holien; Anne Kærsgaard Mylin; Lene Heickendorff; Oddrun Elise Olsen; Anders Sundan; Ingemar Turesson; Peter Gimsing; Anders Waage; Therese Standal
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Acroosteolysis in systemic sclerosis: An insight into hypoxia-related pathogenesis.

Authors:  Simon Siao-Pin; Laura-Otilia Damian; Laura Mirela Muntean; Simona Rednic
Journal:  Exp Ther Med       Date:  2016-10-05       Impact factor: 2.447

3.  The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.

Authors:  Kakeru Ozaki; Takanori Yamada; Tetsuhiro Horie; Atsushi Ishizaki; Manami Hiraiwa; Takashi Iezaki; Gyujin Park; Kazuya Fukasawa; Hikari Kamada; Kazuya Tokumura; Mei Motono; Katsuyuki Kaneda; Kazuma Ogawa; Hiroki Ochi; Shingo Sato; Yasuhiro Kobayashi; Yun-Bo Shi; Peter M Taylor; Eiichi Hinoi
Journal:  Sci Signal       Date:  2019-07-09       Impact factor: 8.192

4.  Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene.

Authors:  Manti Guha; Satish Srinivasan; Alexander Koenigstein; Mone Zaidi; Narayan G Avadhani
Journal:  Ann N Y Acad Sci       Date:  2015-03-18       Impact factor: 5.691

5.  Plasma Growth and Differentiation Factor 15 Predict Longitudinal Changes in Bone Parameters in Women, but Not in Men.

Authors:  Yusuke Osawa; Toshiko Tanaka; Richard D Semba; Giovanna Fantoni; Ruin Moaddel; Julián Candia; Eleanor M Simonsick; Stefania Bandinelli; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-10-06       Impact factor: 6.591

6.  Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome.

Authors:  Zehra Berberoglu; Aynur Aktas; Yasemin Fidan; Ayse Canan Yazici; Yalcin Aral
Journal:  J Bone Miner Metab       Date:  2014-01-16       Impact factor: 2.626

Review 7.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

8.  Transcriptional Modulator Ifrd1 Regulates Osteoclast Differentiation through Enhancing the NF-κB/NFATc1 Pathway.

Authors:  Takashi Iezaki; Kazuya Fukasawa; Gyujin Park; Tetsuhiro Horie; Takashi Kanayama; Kakeru Ozaki; Yuki Onishi; Yoshifumi Takahata; Yukari Nakamura; Takeshi Takarada; Yukio Yoneda; Takashi Nakamura; Jean Vacher; Eiichi Hinoi
Journal:  Mol Cell Biol       Date:  2016-09-12       Impact factor: 4.272

9.  Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.

Authors:  Wenchu Wang; Xin Yang; Jinlu Dai; Yi Lu; Jian Zhang; Evan T Keller
Journal:  Oncogene       Date:  2019-02-12       Impact factor: 8.756

10.  Genome wide analysis indicates genes for basement membrane and cartilage matrix proteins as candidates for hip dysplasia in Labrador Retrievers.

Authors:  Ineke C M Lavrijsen; Peter A J Leegwater; Alan J Martin; Stephen J Harris; Marianna A Tryfonidou; Henri C M Heuven; Herman A W Hazewinkel
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.